The Valley Desk

Clinical trial reportJCO precision oncologyPublished

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Thomas Jefferson University, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
JCO precision oncology
Published
Subject terms
Humans; Neoplasms; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Mutation; Middle Aged; Urinary Bladder Neoplasms
PubMed ID
38603650
PubMed Central ID
PMC11623915
Added to directory
Source checked

Report a correction or request removal